Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Lonza Group

              • Deals

              Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

              SWITZERLAND Switzerland

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing

              Contact the Supplier

              Lead Product(s): TAC01-HER2

              Therapeutic Area: Oncology

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Triumvira Immunologics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 24, 2020

              Details:

              Collaboration, aimed at developing Triumvira’s TAC01-HER2 T-cell therapy for solid tumors, will leverage Lonza’s expertise in process development and the usage of its proprietary Cocoon® Platform.

              Numab Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology

              Contact the Supplier

              Lead Product(s): ND021

              Therapeutic Area: Oncology

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: 3SBio

              Deal Size: $23.8 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing March 09, 2020

              Details:

              With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic.

              PharmaCompass__DigitalAd